Mapping Early-Phase Supply Chain Bottlenecks That Doom Pipelines

By Tatyana Matveeva, Ph.D., Massachusetts General Hospital

The luster of highly anticipated clinical outcomes is a coveted milestone in biopharmaceutical clinical testing, and deservedly so: ostensibly born out of long-awaited IND approvals, safety data, and feasibility studies, such milestones are often years in the making and subject to the vagaries of successful enrollment, operational efficiency, and a robust quality framework. Indeed, as new therapies progress through the phases of clinical trials, what at first seems like operational readiness frequently crumbles under unforeseen challenges. Quality incidents, bespoke material dependencies, limited site capacity, idiosyncratic protocols, or opaque legacy supplier networks governed by regional regulation or geopolitical risk can derail a program long before commercialization.

There is little doubt that such interruptions are enormously costly for sponsors, investors, and, most importantly, patients. The question before sponsors is not whether operations fail despite significant investment and large acquisition deals for apparently production-ready resources; instead, it is why carefully-planned and often well-funded operations grind to a stop. Despite front-end risk assessments and due diligence efforts to enable visibility of key underlying vulnerabilities and effective integration of globally distributed manufacturing assets, the true culprit is often misidentified.

The Seeds Of Failure Typically Root Before IND

The answer lies upstream, in development. Preclinical development is commonly treated as a regulatory formality rather than the strategic foundation of a resilient manufacturing plan. It generates feasibility, safety, and characterization data, enables CMC packages, and bolsters strong IND applications. Yet many sponsors miscast it as an unglamorous step between discovery and measurable success in the clinic. Falling into this trap is among the costliest strategic mistakes study sponsors can make. Not even veterans in the biomanufacturing space are immune to such miscalculation. I’ll explain why.

As a drug progresses through the stages of clinical testing, manufacturing scales up to accommodate the objectives of subsequent clinical trial phases. Scale-up, however, is not equivalent to “more of the same.” It is an evolution in which production continuity depends on predictable, continuous access to raw materials, single‑use systems and critical consumables, qualified vendors, validated logistics, increased monitoring activities, and reproducible tech transfer across sites. Even more importantly, distributed manufacturing models with sponsors outsourcing a growing number of process steps to faraway sites effectively delegate critical operations to partners they cannot always oversee, whose infrastructural and capacity vulnerabilities they cannot adequately assess, and whose own logistics partners’ pressures they have not fully understood.

Early CMC assumptions are often made with a short-term lens: one batch at a single site using locally available reagents. Those assumptions rarely survive the transition to multiple manufacturing organizations across diverse geographic locations, higher production volumes, and regulated commercial supply. Sponsors focused heavily on rapid clinical milestones frequently fail to model the compounding resource needs that accompany each scaling step. When demand outstrips the fragile supply practices drafted during early development, programs face operational breakdowns, protracted rework, inventory overhauls, process drift, and regulatory scrutiny — outcomes that delay or derail clinical timelines, launches, and time to market. It’s a failure in strategic planning that spells irrecoverable losses and delays to sponsors and investors; patients pay the human cost.

The good news is that it is an avoidable failure, if only we look at preclinical development and CMC activities as the foundations of a sustainable manufacturing strategy and thoughtful supply chain integration, and we ask the right questions when attempting to evaluate systems risks or local and global sociopolitical dynamics that may inject uncertainty into critical supply chain pathways. Mapping probable points of failure early on is the key to allocating effort and resources to build redundant support and facilitate oversight at process steps critical to the overall success of the manufacturing enterprise.

The Anatomy Of Biologics CMC Failure

The circumstances conducive to failure vary. Large, experienced sponsors can be blindsided by legacy supply chains and logistical opacity in newly acquired or partnered site networks. They may realize too late that outsourcing product-critical processing steps is no longer beneficial when distal manufacturing nodes underperform because of quality and operational caveats exposed only under global regulatory scrutiny. Regional suppliers may operate under local norms that are incompatible with global GMP expectations; regulatory idiosyncrasies and fragile infrastructure can create hidden single points of failure. Without deliberate supplier qualification, condensed audit practices, variable quality management systems, and regional risk mapping, systemic vulnerabilities multiply as the program scales. Globally distributed manufacturing sites are differentially subject to geopolitical tensions, supply chain integrity risks, and safety of distribution routes. Coordination gaps across regions produce process variability and elevated quality risk, even when the scientific process itself is robust.

Smaller sponsors and academic teams face a different but equally dangerous mismatch: strong scientific programs and limited operational maturity. Academic labs excel at discovery and proof‑of‑concept work but may lack experience in GMP documentation, establishment of quality management systems, supplier qualification, validated cold‑chain logistics, and tech transfer mechanics. Moving from benchtop to cleanroom exposes gaps in procurement strategy, inventory management, and QA governance infrastructure that requires time and expertise to institute. For first‑time sponsors, building a dependable supply architecture requires rethinking procurement practices, developing buffer strategies for long‑lead items, and negotiating supply agreements with geographically diverse vendors — efforts that demand time, capital, and expertise that are often underestimated in early grant‑funded or seed‑stage planning. More often than not, the result is a significant delay in Phase 1 start times, panic as raw materials deliveries encounter delays, shortages, or recalls, and sponsors scrambling to reinforce a weak supply chain strategy that suddenly threatens the feasibility of the trial.

Preventing Failure Begins With A Balanced Supply Chain Strategy

The need for strategic supply chain planning is particularly obvious in the manufacturing of biologics, cell and gene therapies (CGTs), and other advanced therapies (ATPs). While traditional drug manufacturing prioritizes optimizing efficiency and curtailing excess supply procurement, lean inventory can be a fatal flaw in the production of biologics, CGTs, and ATPs.

As these newer therapeutic modalities are inherently variable, vulnerable to environmental fluctuations, temperature excursions, mechanical stress, and operator technical proficiency, batches can and do fail, and costly rework is not uncommon. The availability of well calculated and appropriately stored excess materials and the anticipated built-in delay in batch release are essential to secure batch production and timely delivery to the clinic. Due to the aforementioned sensitivity of biologics and ATPs to a host of environmental factors in addition to traditional risks drug production faces, the existing global pharmaceutical supply chain is not readily equipped to accommodate their streamlined manufacturing and safe distribution over large geographic areas.¹ In turn, biologics require a logistics network with quality controls and compliance oversight that are orders of magnitude more complex than the supply chain designed to handle the distribution of stable drugs and the components involved in making them.

Finally, the timelines of batch release of biologics and ATPs differ significantly from typical quality release timelines for stable pharmaceuticals. While batch release following quality testing may range between days and weeks for traditional medicines, quality release testing for biologics and ATPs can exceed several months, further delaying the administration of therapeutics to patients and adding cost to production. Together, these fundamental differences in manufacturing and distribution considerations make evident the added logistical, operational, supply chain, and quality complexity implicit in the production of advanced therapies, cell and gene therapies, and biologics.² Such complexities are accompanied by the corresponding added costs (and hard-to-quantify risk) associated with the production and administration of those therapies and compounded by shortsighted planning during the preclinical stages.

Thus, early judicious long-term planning of logistics and supply chain redundancies³ provides a resource-saving strategic lever enabling uninterrupted manufacturing and quality testing for safer, more affordable, more accessible novel therapies. Sponsors chasing clinical timelines at the expense of early-stage strategic planning risk failing to model the supply demands of scale‑up, discovering too late that no life cycle supply strategy exists. The result: unwanted delays, discouraged investors, or program failure.

Practical mitigation regardless of the particulars of the therapeutic modality begins early in these critical areas:⁴

• Sponsors must qualify and diversify suppliers, build inventory and cold chain strategies, identify hidden manufacturing bottlenecks and align procurement with clinical timelines, and embed QA and procurement in CMC decision‑making.
• Tech transfers must be planned with vendor capabilities and geographic risks in mind.
• Contractual protections and supply agreements can stabilize availability; LIMS/ERP integration provides traceability and inventory control.

Above all, sponsors must adopt a life cycle mindset:

• Allocate resources during preclinical development to systems that will scale with the product.
• Consider local suppliers seeking to build lasting partnerships and integrate them into the overall supply chain plans for your product.
• Examine carefully the risks of engaging only global players with a massive presence in the supply chain domain, as they may lack the incentive or ability to enact individualized strategies for guaranteed procurement of key ingredients to small-scale trials.

There is safety in incorporating established large suppliers and less prominent local providers who are likely to invest in developing relationships with a long-term view and building a reputation based on responsiveness and reliability.

These investments are sizable, but they are not optional. A program rushed into the clinic without a supply chain strategy risks irrecoverable losses — financially, and, more importantly, in patient access to potentially lifesaving therapies.

Our commitment to patients means that we must build manufacturing strategies that last and continue to develop domestic infrastructures for pharmaceutical supply security.⁵

References:

1. Transforming the Pharmaceutical Supply Chain, Hedley Rees (2026). Print ISBN:9781394244126 |Online ISBN:9781394244157 |DOI:10.1002/9781394244157
2. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cber-regulated-products-possible-causes-shortages
3. https://www.usp.org/supply-chain/build-resilience-and-reduce-drug-shortages
4. https://www.usp.org/sites/default/files/usp/document/public-policy/supply-chain-resilience-policy-paper.pdf
5. https://apicenter.org/wp-content/uploads/2025/03/APIIC-White-Paper-2025-Building-a-Resilient-Domestic-Drug-Supply-Chain.pdf

About The Author:

Tatyana Matveeva focuses on CGMP operational management, compliance oversight, and effective early integration of logistical and supply chain processes in CGMP contexts.